3M to develop seven day analgesic product

Published: 30-Apr-2001


3M Drug Delivery Systems is to develop a transdermally-delivered pain medication product alongside Purdue Pharma. The product will deliver the opioid analgesic fentanyl via a transdermal delivery system. The product, currently undergoing Phase I trials, is designed to provide up to seven days' continuous pain relief for patients with moderate-to-severe pain resulting from cancer, arthritis, trauma, back and disc diseases.

3M will use its proprietary Latitued transdermal syste, a drug-in-adhesive technology that incorporates the drug within the skin-contacting adhesive. The company claims the result is a product that is small, thin, flexible and easy for the patient to apply. The design is also said to optimise dosing regimens for a consistent, predictable delivery rate.

'We believe the transdermal delivery of fentanyl using our Latitude system will provide an effective treatment profile for pateints by prolonging the duration of action and providing consistent pain relief,' said 3M programme manager Joyce Everly.

You may also like